This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Learn the basics of zero-based budgeting, how to implement it from scratch, and why it can boost discipline and savings for beginners.
16,025 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
A top Republican pushes the Senate to consider the House crypto bill amid a fight over stablecoin yields and regulato...
A major Taiwan chipmaker plans to double the size of its Arizona facility, a move Trump touts as a potential steeplec...
As accel acel 2025 earnings loom, investors seek clarity on revenue, margins, and guidance. This guide breaks down wh...
A 740,000-vehicle recall casts a long shadow over Ford's rebound story, threatening brand trust and investor sentimen...
A rising figure in Iran’s shadow government, Mojtaba Khamenei is fueling a debate over who will lead and how the econ...
California aims to curb the so-called buy, borrow, die strategy used by ultra-wealthy as part of a broader billionair...
A new state study finds Latinos are underrepresented in California home purchase lending, with banks lending far less...
Rocket Lab is pursuing a bold $8 billion strategy to merge rocket launches, satellites, and data services. Learn what...
PulteGroup has teamed up with SitecoreAI to unify its marketing, sales, and CRM systems, aiming for a seamless, perso...
Political wrangling and funding gaps create a tightening knot for Social Security. This article explains the math, th...
SOL Strategies' shares jumped about 20% after it disclosed February validator network growth to 33,568 wallets. The m...